Gamma FY2025 slides: 16% profit growth driven by German expansion

Gamma reported FY2025 adjusted EBITDA up 13% to £141.7m and adjusted EPS up 11% to 94.5p, with group gross profit +16% to £348.2m. Germany drove growth with gross profit £78.4m (reported +197%, organic +11% CC) following Starface/Placetel, while net cash of £153.7m at end-2024 became net debt of £9.3m after the £152.2m Starface acquisition. The company returned £64.0m to shareholders (including a £45.1m buyback) and committed ~£125m of returns over two years, but shares dropped ~10.3% to 712 GBP (near a 52-week low) despite a P/E ~10.2 and 3.1% yield.

Analysis

The market has priced the company as a UK-cyclical SME story rather than a Europe-facing recurring-revenue platform with embedded expansion optionality. That view understates the asymmetry between short-term UK churn and longer-dated margin capture from higher-margin continental contracts and channel-led cloud migrations, which typically crystallise over 3-12 months as integrations complete and platform migrations roll out.

Hyperscalers are both threat and distributor: their native voice offerings compress headline pricing but also expand total addressable spend on cloud connectivity, security and AI agents. This creates a two-way flow — win-back opportunities for a quality-of-service operator plus incremental demand for edge/compute and networking kit (a positive for infrastructure vendors) if enterprise customers opt for hybrid deployments instead of hyperscaler-only stacks.

Primary risks are execution (integration and cross-sell), UK SME macro and margin pressure on commoditised connectivity; these are near-term and binary, likely to move sentiment sharply in days-to-weeks around contract renewals or a poor quarterly migration cadence. Conversely, demonstrable deleveraging and one or two visible German account implementations will act as 3-12 month catalysts that materially re-rate the stock if recurring cash conversion proves sustainable.

Contrarian read: investor pessimism is concentrated on short-cycle revenue churn rather than durable economics — if management delivers the announced cost synergies and maintains cash returns, upside is skewed because the market has already priced in a multi-quarter growth miss. Tactical optionality and pair structures are the cleanest ways to express this asymmetry while limiting exposure to the UK SME macrocycle.

Key Decisions for Investors

• Long GAMA (LSE:GAMA) — 12 month target: +35–45% upside vs downside capped ~-30% if UK deterioration accelerates. Position size 2–4% NAV. Add on any >8% post-release retracement or on a confirmed improvement in integration KPIs (net additions / migration run-rate).
• Buy GAMA Jan 2027 LEAP call spread (buy nearer-term LEAP, sell a higher strike) to capture 12–18 month re-rating with defined premium risk; target 3:1 upside-to-premium if synergies and deleveraging timeline are met.
• Long select infrastructure exposure (CSCO, SMCI) — 6–12 month trade to capture incremental spend from hybrid cloud voice and edge compute adoption driven by enterprise migrations. Size modest (1–2% NAV each) as a correlated but de-risked way to play the same secular tailwinds.
• Hedge / risk control: buy short-dated puts on GAMA or size protective hedges if net-debt remains elevated beyond two consecutive quarters or if management delays proofpoints on cost synergy delivery; treat hedges as tactical insurance (cost ~<1–2% NAV).